1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. Stem Cells: An Introduction
2.1 What Are Stem Cells?
2.2 Potency and Differentiation
2.3 Embryonic Stem Cells
2.4 Adult Stem Cells
2.4.1 Haematopoietic Stem Cells
2.4.2 Mesenchymal Stem Cells
2.4.3 Adipose-Derived and Other Stromal Stem Cells
2.4.4 Neural Stem Cells
2.4.5 Other ASCs
2.5 Induced Pluripotent Stem Cells
2.6 Autologous and Allogeneic Properties
2.7 Stem Cells in Medicine: Past, Present and Future
3. The World Stem Cells Market 2012-2022: Overview
3.1 The Stem Cells Market, 2012
3.2 Stem Cells Market Forecast 2012-2022
3.3 Stem Cells Market Segmentation
3.4 What is a Stem Cell Therapy?
3.5 Stem Cells, Progenitor Cells, Cellular Therapies, and Regenerative Medicine
3.6 What is a Stem Cell Product? A Note on the Stem Cell Transplant Market
4. Stem Cell Therapies Market, 2012-2022
4.1 World Market Forecast, 2012-2022
4.2 Existing Stem Cell Therapies, 2012
4.3 Haematopoietic Stem Cell Transplantation Market, 2012
4.3.1 Therapeutic Effectiveness of Stem Cell Transplantation
4.3.2 Graft Versus Host Disease and Other Factors in Stem Cell Transplantation
4.4 World Stem Cell Treatments Market, 2012
4.5 Stem Cell Orthobiologics, 2012
4.5.1 The Use of Stem Cells in Orthobiologics
4.5.2 NuVasive - the Osteocel Product Family
4.5.3 Orthofix - The Trinity Bone Matrix
4.5.4 Osteotech - Harvesting Autologous Bone Marrow Stem Cells
4.5.5 Skye Orthobiologics - Soft Tissue Repair with a Cellular Matrix
4.5.6 SpineSmith - Point-of-Care Bone Marrow Cells for the Spine
4.5.7 RTI Biologics - Rolling Out Stem Cell Orthobiologics from 2012?
4.5.8 BioMet Orthopedics - Trialling the MarrowStim Concentration Kit
4.5.9 MedCell Bioscience - Tendon Therapies
4.5.10 Banc de Sang i Teixits - Bone Repair in Catalonia
4.5.11 Apatech - Observing Outcomes for Stem Cell Grafts
4.5.12 Other Companies in Stem Cell Orthobiologics
4.6 Other Approved Stem Cell Products, 2012
4.6.1 FCB-Pharmicell - Hearticellgram-AMI, the First Approved Product of its Kind
4.6.2 Anterogen - Cupistem, Adipose-Derived Stem Cells for Anal Fistula
4.6.3 Medipost - Cartistem
4.7 Late-Stage Pipeline for Stem Cell Therapeutics
4.7.1 Aastrom Biosciences - Ixmyelocel-T for Critical Limb Ischemia
4.7.2 Gamida Cell - StemEx: A Cord Blood Blockbuster?
4.7.3 Mesoblast - 40-Fold Expansion of Cord Blood Stem Cells
4.7.4 Osiris Therapeutics - Prochymal
4.7.5 Baxter Healthcare - Autologous CD34 Positive Cells for Heart Disease
4.7.6 TiGenix - Cx601 for Complex Perianal Fistula
4.7.7 Bioheart - MyoCell in MARVEL Trial
4.7.8 Cytori Therapeutics - Adipose-Derived Cells for Acute Myocardial Infarction
4.7.9 Stempeutics Research - First Stem Cell Approval in the Indian Market?
4.8 Pipeline for Stem Cell Transplantation Ancillary Products
4.8.1 Mobilisation/Engraftment / Graft Enhancement
4.8.1.1 Bayer - GM-CSF for Mobilisation and other Trials
4.8.1.2 Biokine Therapeutics - BKT140 for Stem Cell Mobilisation and Myeloma Cell Destruction
4.8.1.3 Biothera - Imprime PGG for Progenitor Mobilisation
4.8.1.4 Celldex Therapeutics - CDX-301 Protein to Enhance Harvesting
4.8.1.5 Cytheris - Interleukin-7 for Immune Reconstitution
4.8.1.6 Eisai - Treatments for Sepsis, Nausea and Immune Enhancement
4.8.1.7 Fate Therapeutics - ProHema for Pharmacological Enhancement
4.8.1.8 Genzyme - Plerixafor in Label-Extension Trials
4.8.1.9 Noxxon Pharma - Spiegelmers for Mobilisation
4.8.1.10 Shenzhen Zhongxing Yangfan Biotech - Ex Vivo Activated Immune Cells
4.8.1.11 Systemix - RevM10 Gene Therapy Trial
4.8.1.12 Polyphor - Small Molecule Mobilisation Enhancement
4.8.1.13 TaiGen Biotechnology - Burixafor for Stem Cell Mobilisation
4.8.1.14 Tarix Pharmaceuticals - TXA127 Peptide for Peripheral Stem Cell Populations
4.8.1.15 Xcyte Therapies - Xcellerate Technology for Improving Implantation Outcomes
4.8.2 Anti-Graft versus Host Disease
4.8.2.1 Alder Biopharmaceuticals - ALD518 Antibody
4.8.2.2 AstraZeneca - MEDI-507 for Paediatric Patients
4.8.2.3 Fresenius Biotech - Polyclonal Antibody for Prophylaxis
4.8.2.4 Kiadis Pharma - ATIR for Allogeneic Transplant Enhancement
4.8.2.5 MolMed - Genetically Engineering Lymphocytes
4.8.2.6 PDL BioPharma - Visilizumab in Trials
4.8.2.7 Rafa Laboratories - Budesonide as New Steroid Option
4.8.2.8 Regimmune - Immunomodulator for Allogeneic Transplants
4.8.2.9 Therakos - Photophoresis of Peripheral Blood Cells
4.8.3 New Anti-Infectives
4.8.3.1 AM-Pharma - Antifungal Peptide Trials
4.8.3.2 Astellas Pharma - Micafungin for Paediatric Transplant Recipients
4.8.3.3 Cell Medica - Antiviral Cell Therapies
4.8.3.4 Chimerix - CMX001 Targets Cytomegalovirus
4.8.3.5 Enzon Pharmaceuticals - Anti-Infective Recombinant Lectin Concept
4.8.3.6 Gilead Sciences - AmBisome as Allogeneic Adjunct
4.8.3.7 Johnson & Johnson - Janssen Trialling Antifungal Prophylaxis
4.8.3.8 Merck & Co. - Antifungals for Allogeneic Transplant Assistance
4.8.3.9 Vical - Cytomegalovirus Vaccine Candidate
4.8.3.10 ViroPharma - Maribavir Antiviral in Phase III
4.8.3.11 Xiamen Amoytop Biotech - Biological Anti-Infectives from Shanghai
4.8.4 New Treatments for Combination
4.8.4.1 Abbott - Leuprolide Acetate Depot in Haematological Malignancies
4.8.4.2 AiCuris - AMD3100 in Trials with Busulfan and Other Combinations
4.8.4.3 Alizyme - ATL-104 Targets Mucous Membrane Inflammation
4.8.4.4 Biogen Idec - Combining Radio-Immunotherapy with Transplantation
4.8.4.5 Celator Pharmaceuticals - Acute Myelogenous Leukaemia Candidate
4.8.4.6 CyDex Pharmaceuticals - New Chemotherapeutics in Development
4.8.4.7 Incyte - JAK Inhibitor for Haematological Malignancies
4.8.4.8 Medac - Specialising in the Malignancies Segment
4.8.4.9 Molecular Insight Pharmaceuticals - Iodine-131 Radio-Immunoconjugate Trial
4.8.4.10 Otsuka Pharmaceutical Development & Commercialization - Further Busulfan Trials
4.8.4.11 Pierre Fabre Medicament - Radiotherapy and Chemotherapy Combinations
4.8.4.12 Poniard Pharmaceuticals - Radiation Treatments
4.8.4.13 Swedish Orphan Biovitrum - Oral Mucositis Candidate
4.8.4.14 Spectrum Pharmaceuticals - More Zevalin Combinations
4.8.4.15 TAP Pharmaceutical Products - Secondary Amenorrhea in Transplant Patients
4.8.4.16 Vion Pharmaceuticals - New Alkylating Agent
5. Medium and Long-Term Stem Cell Therapies Pipeline, 2012
5.1 Overview of the Stem Cell Pipeline, 2012
5.2 Oncology: Cancer Stem Cells and Other New Treatment Possibilities
5.2.1 Amgen: Cell Transplantation for Metastatic Renal Cell Carcinoma
5.2.2 Cellerant Therapeutics - Engraftment Enhancement and a Cancer Stem Cell Antibody
5.2.3 ImmunoCellular Therapeutics - Glioblastoma Stem Cell Target
5.2.4 Immunovative Therapies - Mirroring the Stem Cell Transplantation Anticancer Effect
5.2.5 Novartis Pharmaceuticals - Cord Blood Transplant Candidate
5.2.6 Ribozyome - Stem Cell Gene Therapy Concept for Hodgkin's Lymphoma
5.3 Autoimmune Diseases - Using Stem Cells to Reset the Immune System
5.3.1 Alliancells Bioscience Corporation - Possible Rheumatoid Arthritis Treatment
5.3.2 AlloCure - AC607 for Anti-Inflammatory Effects
5.3.3 Athersys - MultiStem for Autoimmune and Other Disorders
5.3.4 Celgene Corporation - Placental Tissue Stem Cells for Rheumatoid Arthritis and Others
5.3.5 HomeoTherapy - Mesenchymal Stem Cells for GvHD
5.3.6 ViroMed - Stem Cell Gene Therapy for Chronic Granulomatous Disease
5.4 Diabetes - Stem Cells to Restore Pancreatic Function
5.4.1 Cellonis Biotechnology - Commercializing Peking University Research on Stem Cells in Diabetes
5.4.2 Ixion Biotechnology - Liver Stem Cells for Insulin Production
5.4.3 MaRS Innovation - Diabetes Partnership with Mount Sinai Hospital
5.4.4 ViaCyte - Encaptra System for ESC-Produced Pancreatic Precursors
5.5 Cardiological/Cardiovascular Diseases - Stem Cells to Heal the Heart and Vascular System
5.5.1 Aldagen - Proprietary Cells for Ischemic Conditions
5.5.2 Apceth - Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
5.5.3 Athersys - Angiotech Collaboration
5.5.4 Biogenea-Cellgenea - Cardiogenea for Myocardial Infarction
5.5.5 Capricor - Using Cardiosphere-Derived Cells for Heart Repair
5.5.6 Cardio3 Bioscience - Cardiopoiesis Platform for Heart Regeneration
5.5.7 Cardiogenesis Corporation - Lasers and Stem Cells for Revascularisation
5.5.8 Eli Lilly and Company: Collaborating on Intracoronary Injection of Progenitor Cells Trial
5.5.9 Garnet BioTherapeutics - GBT009 for Cardiac Tissue Preservation
5.5.10 Medistem - Endometrial Regenerative Cells for Critical Limb Ischemia
5.5.11 Neostem - AMR-001 for Myocardial Infarction
5.5.12 Northern Therapeutics - Gene Therapy for Pulmonary Arterial Hypertension
5.5.13 OrbusNeich - Coronary Stent Activates Endogenous Cell Populations
5.5.14 Pluristem Therapeutics - Placental Stem Cells for Peripheral Artery Disease
5.5.15 Regenetech - Heart Disease Treated with NASA-Derived Tissue Technology
5.5.16 TCA Cellular Therapy - Mesendo Autologous Treatments
5.6 Neurological/Cerebrovascular Disease - Regenerating Brain, Nerves and Vasculature
5.6.1 New Paradigms in Neurodegenerative Disease Treatment
5.6.2 BrainStorm Cell Therapeutics - NurOwn Cells for Spinal Cord Injury and ALS
5.6.3 Corestem - Autologous Bone Marrow Stem Cells for ALS
5.6.4 Geron Corporation - ESC Pioneer
5.6.5 Neuralstem - Neural Stem Cells for Synaptic Repair and Neuroprotection
5.6.6 NeuroGeneration - Parkinson's Treatment with Autologous Neural Stem Cells
5.6.7 NsGene - Encapsulated Cell Biodelivery System
5.6.8 Proneuron Biotechnologies - CNS Cellular Therapies
5.6.9 ReNeuron - Foetally-Derived CTX Cells for Stroke
5.6.10 Renovo Neural - Cellular Multiple Sclerosis Treatments
5.6.11 RhinoCyte - Stem Cells from the Nasal Passage to the Spinal Cord
5.6.12 Saneron CCEL Therapeutics - U-CORD-CELL Preclinical Platform
5.6.13 StemCells - Clinical Trials in Batten Disease and Others
5.6.14 Stem Cell Therapeutics - NTx-265 for Stroke
5.6.15 SanBio - SB623 for Ischemic Stroke
5.6.16 Stemedica Cell Technologies - Ischemic Tolerant Stem Cell Platform
5.6.17 Theradigm - Neural Cells for CNS Disorders
5.6.18 Titan Pharmaceuticals - Dopaminergic Cell Treatment Concept
5.7 Ophthalmic Disease - Chief Focus for ESC Clinical Work
5.7.1 ArBlast - Treating Corneal Disorders and Other Diseases
5.7.2 Advanced Cell Technology - Leading the Field in ESC Clinical Trials
5.7.3 Biotime - Targeting AMD with ESCs
5.7.4 CellSeed - CAOMECS for Cornea Repair
5.7.5 Pfizer - Collaborating on the London Project to Cure Blindness
5.8 Other Areas of Investigation for Stem Cell Therapies
5.8.1 Alliqua - HepaMate Bioartificial Liver and Stem Cells
5.8.2 CellTran - Cellular Skin Repair Products
5.8.3 GlaxoSmithKline - Collaborating with Harvard Stem Cell Institute
5.8.4 Histogen - Hair Stimulating Complex Contains Stem Cell Factor
5.8.5 IntelliCell Biosciences - Adipose-Derived Stem Cells for Autologous Treatments
5.8.6 Intercytex - Formerly Owned Axordia Stem Cell Research
5.8.7 iPierian - IPSC Expertise
5.8.8 Medtronic - Links to MG Biotherapeutics and Tengion
5.8.9 Odontis - BioTooth for Dental Replacement Concept
5.8.10 Roche - Research Collaborations in the Field
5.8.11 S-Evans Biosciences - Menstrual Stem Cells for Hepatic Disease
5.8.12 Tengion - Neo-Organs from Progenitor Cells
5.8.13 Tissue Genesis - First Point-of-Care Study of Adipose-Derived Stem Cells to be FDA-Approved
5.8.14 Vesta Therapeutics - Regenerating the Liver with Stem and Progenitor Cells
6. Stem Cell Banking Market, 2012-2022
6.1 World Market Forecast, 2012-2022
6.2 Health Insurance for the Cellular Therapy Century: Overview of the Stem Cell Banking Field
6.3 Selected Companies in the Stem Cell Banking Field
6.3.1 Amstem Corporation - Former Leader in the Field
6.3.2 China Cord Blood Corporation - China's Biggest Blood Bank
6.3.3 Cord Blood America - Presence in the US, Latin America and Europe
6.3.4 Cryo-Cell - First Private Cord Blood Bank
6.3.5 CryoCord - Leaders in Malaysia
6.3.6 Cryo-Save - Europe's Largest Stem Cell Bank
6.3.7 General BioTechnology - Stem Cells for Banking and Veterinary Therapies
6.3.8 InSCeption Biosciences - Canada's Biggest Cord Blood Programme
6.3.9 International Stemcell Services - First Indian Umbilical Cord Blood Bank
6.3.10 LifebankUSA - First Transplanted Placental Cells
6.3.11 Lifebank Cryogenics - Canada's First Cord Blood Bank
6.3.12 Stem Cell Authority - Banking Mesenchymal Cells
6.3.13 Stem Cell Sciences - Banking Adult Haematopoietic Stem Cells
6.3.14 StemCyte - High Stem Cell Yield
6.3.15 ViaCell - ViaCord Umbilical Cord Blood Bank
7. Stem Cell Ancillaries Market, 2012-2022
7.1 World Market Forecast, 2012-2022
7.2 Overview of Stem Cell-Related Business Models, 2012
7.3 Stem Cell Assays: An Important Field
7.3.1 Axiogenesis - In Vitro Disease Models
7.3.2 Cellectis Group - First Marketed Cardiomyocytes and Hepatocytes Derived from ESCs
7.3.3 Cellular Dynamics International - Leader in IPSC Technology
7.3.4 CXR Biosciences - Drug Development and Toxicology Services
7.3.5 Maxcyte - Stem Cells in Early Phase Drug Discovery
7.3.6 Stemina Biomarker Discovery - ESCs and Metabolomics
7.4 Stem Cell Supply and Processing: Products and Services
7.4.1 3DM - PuraMatrix for Cell Culturing
7.4.2 Adistem - Extraction and Activation Technology Platform
7.4.3 AllCells - Stem Cell Line Supplier
7.4.4 Angel Biotechnology - Stem Cell Contract Biomanufacturing
7.4.5 Antria - Regenerative Medicine Contract Research Organisation
7.4.6 Arteriocyte - Nanex Culturing and Expansion Technology
7.4.7 BioE - Marketing the First Multipotent Clonal Stem Cell Line from Umbilical Cord Blood
7.4.8 Bio-Matrix Scientific Group - Stem Cell Cryobanking, Research and Partnerships
7.4.9 Cognate BioServices - Custom Manufacture and Testing of Stem Cells
7.4.10 EpiStem - Epithelial Stem Cell Specialists
7.4.11 FortiCell Bioscience - Biomaterials Technology Platforms
7.4.12 Global Stem - Growth Media, Reagents and Other Stem Cell Tools
7.4.13 Miltenyi Biotec - MACSQuant Analyzer and Other Stem Cell Tools
7.4.14 Plasticell - CombiCult Differentiation Platform
7.4.15 Roslin Cellab - ESC Lines and Other Resources
7.4.16 StemCell Technologies - Stem Cell Culturing, Isolation, Training and Other Services
7.4.17 StemCore - Pluripotent Cell Lines and Outsourcing Services
7.4.18 Stemride International - Normal and Abnormal ESC Lines
7.4.19 Vitro Biopharma - Tools for Stem Cell and Drug Development
7.5 Supporting Technologies
7.5.1 BioLife Solutions: HypoThermosol and CryoStor Biopreservation
7.5.2 CellCentric: Epigenetics and Cell Reprogramming Expertise
7.5.2.1 Stem Cells and Epigenetics: Brief Discussion
7.5.3 CellCyte Genetics - CCG-E45 Culture Chamber
7.5.4 Covance - Heavy Involvement with Biological Drug Development
7.5.5 ThermoFisher Scientific - Instruments, Equipment, Software and Other Medical Technology
7.5.6 ThermoGenesis - BioArchive System and Other Proprietary Technologies
8. Stem Cells Market Regional Overview 2012
8.1 US: Controversy and Venture Capital
8.2 UK: Leading the Way in Europe
8.3 Europe: Mixed Responses
8.4 Israel: A Nexus of Stem Cell Innovation
8.5 Japan: Home of IPSC Research
8.6 India: High Activity in the Field
8.7 China: A Potential Leader in Stem Cells
8.8 South Korea: First to Approve Stem Cell Treatments
9. Main Research Interviews from Our Survey
9.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
9.1.1 Current Stem Cell Clinical Trials
9.1.2 Big Pharma Investment in Stem Cells
9.1.3 Mesenchymal Cells in Clinical Trials
9.1.4 Definitions of Cell Types and Regulatory Pathways
9.1.5 The Prospects for Stem Cell Cures
9.2 Interview with Nick Bassil, Partner, Kilburn & Strode LLP
9.2.1 Overview of the Stem Cell Patent Landscape
9.2.2 The Aftermath of the Brüstle Case
9.2.3 Details and Consequences of the Brüstle Ruling
9.2.4 Patenting Adult Stem Cells and Induced Pluripotent Stem Cells
9.2.5 Stem Cell Regulation and Stem Cell Ethics
9.3 Interview with Dr Kieran Breen, Director of Research and Innovation, Parkinson's UK
9.3.1 Damage to Neural Matter Caused by Parkinson's Disease
9.3.2 The Limitations for Stem Cell Treatment of Parkinson's Disease
9.3.3 The Therapeutic Prospects for Induced Pluripotent Stem Cells
9.3.4 The Likelihood of a Sustained Response to Regenerative Treatments of Parkinson's Disease
9.4 Interview with Jason Kolbert, MBA, Vice President of Strategic Business Development, NeoStem
9.4.1 NeoStem's Business Model
9.4.2 NeoStem's AMR-001 Candidate
9.4.3 The Regulatory and Commercial Challenges for AMR-001
9.4.4 NeoStem's VSEL and Blood Banking Platforms
9.4.5 The Broader Stem Cell Therapies Market to 2022
9.5 Interview with Mr Felix von Haniel, Director, Business Development, Axiogenesis
9.5.1 Axiogenesis' Tissue Production Platform
9.5.2 Modelling Cardiac Hypertrophy
9.5.3 Future Trends in the Stem Cells Assays Market
9.5.4 The Potential for iPSCs
10. Conclusions
10.1 Strengths: Stem Cells Have Proven Clinical and Commercial Value
10.2 Weaknesses: The Field is Still in its Infancy
10.3 Opportunities: A Revolution in Medicine?
10.4 Threats: A Controversial Field
10.5 Concluding Remarks
List of Tables
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 2.3 Sources of Stem Cells for Medical Applications, 2012
Table 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
Table 3.2 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.3 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2022
Table 4.1 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 4.2 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 4.3 Medicare Coverage for HSCT, 2012
Table 4.4 Malignancies and Other Haematological Diseases Treated with HSCT, 2012
Table 4.5 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2012
Table 4.6 Orthobiologics Market: Segment Revenues ($bn) and Market Shares (%), 2011
Table 4.7 Selected Players in Stem Cell Orthobiologics
Table 4.8 Companies with Stem Cell Products Approved by the Korean FDA
Table 4.9 Selected Approved (Non-Stem Cell) Cellular Therapies, 2012
Table 4.10 Stem Cell Therapies in Phase III Development, 2012
Table 4.11 Selected Non-Industry Sponsored Phase III Stem Cell Trials, 2012
Table 4.12 Aastrom Biosciences' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.13 Gamida Cell's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.14 Mesoblast's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.15 Osiris Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.16 Baxter Healthcare's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.17 Cellerix's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.18 Bioheart's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.19 Cytori Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.20 Stempeutics Research's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.21 Selected Companies with Candidate Stem Cell Transplantation Ancillary Products, 2012
Table 5.1 Quantity of Stem Cell Clinical Trials by Indication, 2012
Table 5.2 Selected Companies Developing Stem Cell Treatments for Cancer, 2012
Table 5.3 Selected Companies Developing Stem Cell Autoimmune Treatments, 2012
Table 5.4 Selected Companies Developing Stem Cell Diabetes Treatments, 2012
Table 5.5 Selected Companies Developing Stem Cell Cardiological/Cardiovascular Treatments, 2012
Table 5.6 Selected Companies Developing Stem Cell Neurological/Cerebrovascular Treatments, 2012
Table 5.7 Selected Companies Developing Stem Cell Ocular Treatments, 2012
Table 6.1 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 6.2 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 6.3 Reported Fees of Various Private Stem Cell Blood Banks Worldwide, 2011
Table 7.1 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 7.2 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 7.3 Selected Companies Offering Stem Cell-Based Assays, 2012
List of Figures
Figure 2.1 The Early History of Stem Cell Discovery and Development
Figure 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
Figure 3.2 Stem Cells Market by Segment: Revenues ($m), 2011-2016
Figure 3.3 Stem Cells Market by Segment: Revenues ($m), 2017-2022
Figure 4.1 Stem Cell Therapies Market: Revenues ($m), 2011-2016
Figure 4.2 Stem Cell Therapies Market: Revenues ($m), 2017-2022
Figure 4.3 Orthobiologics Market Shares (%), 2011
Figure 5.1 Quantity of Stem Cell Clinical Trials (All Phases) by Indication, 2012
Figure 5.2 Oncology Stem Cell Clinical Trials by Phase, 2012
Figure 5.3 Cardiological/Cardiovascular Stem Cell Clinical Trials by Phase, 2012
Figure 5.4 Autoimmune, Diabetes, Neurological and Ophthalmological Stem Cell Clinical Trials by Phase, 2012
Figure 5.5 Pfizer's Stem Cell Collaborations, 2008-2012
Figure 6.1 Stem Cell Banking Market: Revenues ($m), 2011-2016
Figure 6.2 Stem Cell Banking Market: Revenues ($m), 2017-2022
Figure 6.3 Reported Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
Figure 7.1 Stem Cell Ancillaries Market: Revenues ($m), 2011-2016
Figure 7.2 Stem Cell Ancillaries Market: Revenues ($m), 2017-2022
Figure 7.3 High Profile Toxicity-Related Pharmaceutical Product Withdrawals, 1991-2010
Figure 7.4 Pharmaceutical R&D Spending by Developmental Stage, 2010
Figure 10.1 Stem Cell Market Segments: Revenues ($m), 2011-2022